Paraneoplastic Antigen Ma2 Autoantibodies as Specific Blood Biomarkers for Detection of Early Recurrence of Small Intestine Neuroendocrine Tumors Abstract #193

Introduction: Small intestine neuroendocrine tumors (SI-NETs) are rare fatal cancers. Many patients develop metastatis before diagnosis. There is no available curative treatment for patients with metastasis.
Aim(s): Ma2 is a new SI-NET biomarker. The goal is to evaluate whether anti-Ma2 detection in the blood is useful for clinical patient management.
Materials and methods: A novel indirect enzyme-linked immunosorbent assay (ELISA) was set up to detect Ma2 autoantibodies in blood. One-hundred and ninety blood samples from patients with SI-NET, typical and atypical lung carcinoids, different stage of disease, were used. Immunohistochemistry, Western blot, Sequential Immunoprecipitation and Immuno-Dot-blot analyses were used in the study.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Associate Profes Valeria Giandomenico

To read results and conclusion, please login ...

Further abstracts you may be interested in

#20 Paraneoplastic antigen Ma2 (PNMA2) auto-antibodies as biomarkers for early small intestine neuroendocrine tumors detection
Introduction: Small intestine neuroendocrine tumors (NETs) comprise well-differentiated NET (benign carcinoid), well-differentiated neuroendocrine carcinoma (malignant carcinoid) and poorly differentiated neuroendocrine carcinoma (NEC). The majority of NET patients have developed liver metastases at the time of diagnosis and surgery is then seldom curative. Novel predictive, diagnostic and prognostic markers are thus needed to improve our capabilities to diagnose and cure these tumors. We have previously identified six novel marker genes for neuroendocrine tumor cells by using Affymetrix microarrays and advanced bioinformatics. One of this markers, the paraneoplastic antigen Ma2 (PNMA2), which is normally expressed only in nervous tissue, can in the process of carcinogenesis be detected in tumors located outside the nervous system. The finding that Ma2 is expressed in small intestine neuroendocrine primary tumors and their metastases made it interesting to screen whether antibodies against Ma2 are present in the serum of NET patients.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: PhD Valeria Giandomenico
Authors: Cui T, Elgue G, Li S C, Hurtig M, ...
#672 Affinity Proteomic Plasma Analysis of Human Well-Differentiated Small Intestinal Neuroendocrine Tumors
Introduction: Small intestine neuroendocrine tumor (SI-NET) patients get diagnosis at the stage of metastasis and there is a lack of curative treatments.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Assoc. Prof, PhD Valeria Giandomenico
Authors: Darmanis S, Cui T, Li S C, Öberg K, ...
#2854 A Meta-Analysis of the Accuracy of a Neuroendocrine Tumor mRNA Genomic Biomarker (NETest) in Blood
Introduction: The lack of an accurate blood biomarker in neuroendocrine tumor (NET) disease impedes effective management.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
Authors: Öberg K, Califano A, Strosberg J, Ma S, ...
#2849 PRRT Neuroendocrine Tumor Response Assessment Using Circulating Transcript Analysis: The NETest
Introduction: The absence of an accurate blood biomarker to predict and monitor PRRT is a key unmet need.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
#2926 O-Positive Blood Group Is Associated with Prolonged Recurrence-Free Survival Following Pancreatic Neuroendocrine Tumor (PanNET) Curative-Intent Surgical Resection
Introduction: The ABO blood group may influence the development and progression of cancer. In particular, the prognosis of pancreatic adenocarcinoma is better in patients with blood group O. This has not been extensively explored in PanNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Louis de Mestier